share_log

Oppenheimer Initiates Coverage On Y-mAbs Therapeutics With Outperform Rating, Announces Price Target of $23

Oppenheimer Initiates Coverage On Y-mAbs Therapeutics With Outperform Rating, Announces Price Target of $23

Oppenheimer以跑贏市場的評級開始對y-mabs therapeutics進行覆蓋,宣佈股價目標爲23美元
Benzinga ·  2024/11/18 08:48  · 評級/大行評級

Oppenheimer analyst Jeff Jones initiates coverage on Y-mAbs Therapeutics (NASDAQ:YMAB) with a Outperform rating and announces Price Target of $23.

奧本海默分析師傑夫·瓊斯對y-mabs therapeutics(納斯達克:YMAB)開始覆蓋,給予"跑贏大盤"評級,並宣佈目標價爲23美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論